⚠ DEVELOPMENT TERMINATED · CANCER ACCELERATION IN ALL TISSUES TESTED · WADA-BANNED
GlaxoSmithKline terminated GW501516 development in 2007 after carcinogenicity testing showed cancer acceleration in every tissue studied. WADA banned it in 2009 and issued an unusual explicit public warning. The endurance effects are real. The cancer-accelerating mechanism is also real. This page presents both honestly.
Endurance performance · Fat oxidation · Body composition · Exercise mimetic — all preclinical goals; development terminated before Phase III
Regulatory status
Not FDA-approved · Development TERMINATED by GSK 2007 due to cancer acceleration findings · WADA-banned since 2009 with explicit public warning · Research chemical
Human evidence
Limited — Phase I/II data confirming endurance and metabolic effects before development terminated. No safety data beyond short-term trials.
Preclinical evidence
Strong for endurance/metabolic effects AND strong for cancer acceleration — the reason development ended.
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
What is Cardarine?
Cardarine (GW501516) produced some of the most impressive endurance data ever seen in an investigational compound. In the landmark 2008 Cell paper by Narkar et al., Cardarine combined with AICAR produced a 75% improvement in running endurance in untrained mice — without any exercise. Alone, Cardarine produced 44% improvement. Human Phase II trials confirmed metabolic effects: improved fat oxidation, reduced triglycerides, improved insulin sensitivity, and increased HDL. The performance and metabolic data was genuinely exceptional.
Then GSK ran mandatory carcinogenicity testing. In all tissues studied — liver, bladder, stomach, skin, tongue, uterus, ovary — GW501516 accelerated the development of cancer. Not caused cancer in otherwise healthy animals. Accelerated pre-existing or chemically induced cancer. GSK terminated development in 2007. WADA banned GW501516 in 2009 and issued an unusual explicit public warning — not standard practice for banned substances.
Despite this, Cardarine has remained one of the most widely used performance compounds in bodybuilding and endurance communities, primarily because the endurance effects are dramatic and the cancer risk is not immediately visible. This page covers Cardarine because evidence-honest coverage of both the performance effects and the cancer risk is more useful than ignoring it. The cancer risk is real. The endurance effects are real. Both must be understood.
How it works
PPAR-delta Agonism — Endurance and Fat Oxidation
PPAR-delta (PPARδ) is a nuclear receptor regulating genes involved in fatty acid oxidation, mitochondrial biogenesis, and fiber type switching in skeletal muscle. PPAR-delta activation drives increased fat oxidation enzymes (CPT1, MCAD), shift from glycolytic to oxidative muscle fibers, increased mitochondrial density via PGC-1α, improved insulin sensitivity via GLUT4 upregulation, and increased HDL via ABCA1. The result is a metabolic state resembling an endurance-trained athlete — without the training.
The Cancer Acceleration Mechanism — Same Receptor, Same Problem
PPAR-delta is expressed throughout the body — including in cancer cells, where PPAR-delta activation promotes proliferation, survival, and angiogenesis (blood vessel growth into tumors). The pro-proliferative effect of PPAR-delta is mechanistically linked to its pro-metabolic effects: both require activation of the same receptor and the same downstream gene expression programs. The cancer-accelerating and performance-enhancing effects of GW501516 are not separable — they come from the same molecular mechanism.
The AICAR Combination
The 75% endurance improvement in the 2008 Cell paper required combining GW501516 with AICAR (the AMPK activator). PPAR-delta activates fat oxidation gene expression. AMPK activates the mitochondrial biogenesis and energy sensing that makes those genes functionally relevant. Together they produce synergistic endurance improvement. This synergy is why AICAR alone produces less dramatic effects than the combination — but AICAR without the cancer-accelerating PPAR-delta component is a safer approach for the endurance goal.
What the research shows
STUDYCell · 2008
AMPK and PPARdelta agonists are exercise mimetics
Narkar VA et al.
Untrained mice. GW501516 alone: 44% endurance improvement. GW501516 + AICAR: 75% endurance improvement. The paper that established the exercise mimetic concept and prompted WADA to ban both compounds. The performance data is real and exceptional.
STUDYJournal of the American Heart Association · 2012
GW501516 improves lipid profiles and insulin sensitivity — Phase II
Olson EJ et al.
Obese men, GW501516 2.5–10 mg/day for 12 weeks. Significant triglyceride reduction, HDL increase, insulin sensitivity improvement. Confirmed the metabolic effects in humans. Development was already terminated when this was published — underscoring that the metabolic effects are real and the termination was about safety, not efficacy.
GSK's mandatory carcinogenicity studies showed GW501516 accelerated cancer development in liver, bladder, stomach, skin, tongue, uterus, and ovary in animal carcinogenicity models. WADA issued an explicit public warning (unusual for a banned substance) in 2013: "Research has shown that GW501516 — and other similar chemicals — caused cancer to develop rapidly in several organs, such as the liver, tongue, skin, urinary bladder, stomach and other organs in animal studies."GSK's scientists found the data disqualifying enough to terminate a profitable drug program.
✓Cancer acceleration in ALL animal tissues studied — liver, bladder, stomach, skin, tongue, uterus, ovary
✓The cancer-accelerating and endurance-enhancing effects are mechanistically inseparable (same PPAR-delta pathway)
✓Development terminated by GSK 2007; WADA-banned 2009 with explicit public warning
?UNCERTAIN
?Whether cancer acceleration at typical human doses produces clinically meaningful cancer risk over 8-week cycles
?Whether any user population can use it safely — zero long-term human safety data exists
?Whether brief low-dose exposure carries meaningfully lower cancer risk than longer or higher-dose use
AI COACH PREVIEW
I want to use Cardarine for endurance. What does the cancer risk actually mean in practice and what safer alternatives exist?
The cancer risk means exactly what GSK's scientists thought it meant — which is why they terminated a profitable drug program. That's the honest answer. The mechanism is real: PPAR-delta activation promotes cell proliferation broadly, including in cancer cells. The fact that this shows up in carcinogenicity testing across every tissue studied isn't a marginal finding. For someone already making informed decisions about research compounds — who understands the evidence grade and accepts risk accordingly — the calculus is yours to make. But I won't soften what the data shows. On safer alternatives for the same goal: AICAR is the most direct comparison. It produces meaningful endurance improvement via AMPK activation without PPAR-delta's cancer-accelerating mechanism. The effect magnitude is less dramatic than GW501516 (~25-30% endurance improvement vs. 44%), but the preclinical safety profile is categorically different. MOTS-c activates AMPK in muscle and mitochondria with an exceptionally clean safety profile and some human evidence. SLU-PP-332 (ERR agonist) has limited published carcinogenicity data — it's earlier in research than GW501516 was when the cancer findings emerged. If endurance is the specific goal: AICAR is the compound I'd point to.
CONTINUE IN THE APP
Open PepperLedger to track your Cardarine protocol →
Free to join. If you proceed, systematic tracking and any available cancer screening is essential. The Coach understands the risk profile.
Free to join · No credit card · 23-day Pro trial included